FVFI
MCRB icon

Flagship Ventures Fund IV’s Seres Therapeutics MCRB Stock Holding History

Flagship Ventures Fund IV’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		$374M Buy
+704,179
New +$368M 97.96% 1

Other funds holding MCRB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
FVF2
Flagship Ventures Fund 2007 Cambridge, Massachusetts $95.2M AUM
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Flagship Ventures Fund IV's MCRB Position: Q1 2016 in Review

Flagship Ventures Fund IV opened a new position in Seres Therapeutics (MCRB) in Q1 2016: 704,179 shares worth $374M. The stake represents 97.96% of the portfolio and ranks #1 among its holdings.

76 funds tracked by Wall St. Rank hold MCRB as of Q1 2016.

  • Flagship Ventures Fund IV held 704,179 shares of Seres Therapeutics worth $374M as of Q1 2016.
  • Seres Therapeutics was a new Flagship Ventures Fund IV position in Q1 2016.
  • Seres Therapeutics made up 97.96% of Flagship Ventures Fund IV's portfolio in Q1 2016, its #1 holding.
  • 76 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2016.

Based on Flagship Ventures Fund IV's 13F filing for Q1 2016, filed 13 May 2016.